Generic GALLIUM GA-68 EDOTREOTIDE INN equivalents, drug patent expiry and freedom to operate

Sponsor	Phase
Jiangsu HengRui Medicine Co., Ltd.	Phase 3
M.D. Anderson Cancer Center	Early Phase 1
National Cancer Institute (NCI)	Early Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Methodist	GALLIUM GA 68 EDOTREOTIDE	gallium ga-68 edotreotide	SOLUTION;INTRAVENOUS	218845-001	Oct 10, 2025	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Uihc Pet Imaging	GALLIUM GA 68 EDOTREOTIDE	gallium ga-68 edotreotide	SOLUTION;INTRAVENOUS	210828-001	Aug 21, 2019	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: June 10, 2026

GALLIUM GA-68 EDOTREOTIDE market dynamics and financial trajectory: exclusivity, pricing, volumes, and competitive patent pressure

Gallium Ga 68 edotreotide (tradename not used here due to source constraints in this dataset) is a radiopharmaceutical diagnostic imaging agent used for neuroendocrine tumor (NET) localization, typically as a somatostatin receptor–targeted PET tracer. Its market is shaped by: (1) centralized manufacturing and short shelf-life logistics, (2) country-by-country reimbursement and capital requirements for PET adoption, (3) competition from alternative somatostatin receptor PET tracers, and (4) patent and regulatory exclusivity on production, formulation, and use.

Key takeaways for commercialization and valuation: demand correlates to PET/CT growth and NET incidence detection, but unit economics are sensitive to generator supply, GMP capacity, regional pricing, and reimbursement. Financial trajectory is likely “lumpy” by geography because adoption follows infrastructure and payor policy, not pure clinical uptake.

How big is the Gallium Ga 68 edotreotide market and what drives demand?

Answer: Demand tracks PET imaging penetration and NET diagnostic intensity. Uptake is constrained by radiopharmacy capacity, tracer availability, and reimbursement policy.

Core demand drivers

PET/CT expansion: NET workups increasingly use PET rather than planar or SPECT, with higher sensitivity for somatostatin receptor imaging.
Clinical guideline alignment: Somatostatin receptor PET is incorporated into NET staging and restaging pathways in multiple jurisdictions.
Healthcare system reimbursement: Patient access hinges on coverage rules for PET studies and radiotracer reimbursement rates.
Regional oncology testing volume: Areas with higher NET detection and oncology center density generate more imaging demand.
Supply reliability: Imaging scheduling is sensitive to batch availability due to the practical handling and distribution constraints typical of Ga-68-based tracers.

Key market constraints

Short-lived radionuclide logistics: Requires local or near-local radiopharmacy distribution and tight scheduling windows.
Radiopharmacy capex and licensing: Centers need hot-lab operations, QC release workflows, and authorized procurement routes.
Competition between radiotracers: Alternative somatostatin receptor agents can shift utilization when reimbursement or perceived performance changes.

What is the financial trajectory for Gallium Ga 68 edotreotide sales (growth pattern, volatility, and margin pressures)?

Answer: Sales typically show regional growth with uneven timing, with margins pressured by radiopharmacy operations, QC, and radionuclide procurement costs, plus competition-driven price compression.

Likely revenue shape

Early expansion: Slow initial ramp tied to PET adoption and radiopharmacy network build-out.
Mid-cycle growth: Broadening of NET diagnostic and treatment-planning use across oncology centers.
Later-stage volatility: Price and volume swings driven by regional tender outcomes, supply disruptions, and payer policy changes.

Unit economics and margin sensitivity

Radionuclide and precursor cost: The Ga-68 supply chain economics can dominate gross margin.
Release testing and QC labor: Increased testing stringency and faster release windows can increase fixed and variable costs.
Distribution model: Whether supply is centralized or distributed via multiple licensed sites changes cost structure materially.
Competition: Alternative tracers and “in-class” substitutes can compress net price via formulary decisions.

Commercial KPIs to watch

Imaging volume per PET center
Average reimbursed price per scan
Supply fill rate and lead time performance
Tender frequency and average discount rate in each major market

What patents protect Gallium Ga 68 edotreotide and how do they affect market entry timing?

Answer: Product and process protection for radiopharmaceuticals is typically layered. In practice, market entry risk comes from: (1) composition and pharmaceutical formulation claims, (2) manufacturing process claims, and (3) method-of-use claims tied to imaging or diagnostic indications. Exclusivity timing affects who can legally supply and what variants can be substituted.

Where patent risk concentrates for radiotracers

Production process: Claims around preparation steps, labeling conditions, and QC-release criteria.
Formulation and kit composition: Claims that constrain substitution of excipients or kit components.
Use and dosing regimens: Imaging timing, administration characteristics, and intended diagnostic use.

How patent estates typically translate into commercial outcomes

Near-term defense: Patent-protected production and kit claims can limit “drop-in” supply.
Long-tail pressure: Process “design-arounds” and partial use coverage can weaken exclusivity without fully invalidating core patents.
Regulatory strategy alignment: Legal clearance often dictates how quickly new suppliers can commercialize.

When does exclusivity expire for Gallium Ga 68 edotreotide and when do generics or alternatives realistically launch?

Answer: Real launch timing depends on the intersection of regulatory status and the last-to-expire enforceable patent covering the specific marketed presentation and use.

Exclusivity-driven timeline mechanics

Regulatory exclusivity (if applicable in the relevant jurisdiction) delays generic substitution even absent patent enforcement.
Patent expiration enables lawful marketing only if no remaining enforceable claims block manufacturing, labeling, or use.
Paragraph IV-style mechanisms are generally relevant for conventional small molecules; for radiopharmaceuticals, the practical path often turns on regulatory approval pathways and patent carve-outs rather than a direct apples-to-apples Paragraph IV construct.

Commercial outcome mapping

Pre-expiration: Incumbent pricing power is higher, but tender competition increases as future supply becomes visible.
Post-expiration: Margins face compression first in geographies where reimbursement rules allow substitution or where competing tracers have already established distribution.

What generic entry risks exist for Gallium Ga 68 edotreotide?

Answer: The main entry risk is not only “generic” substitution but the ability to manufacture and release a clinically interchangeable Ga-68 radiopharmaceutical presentation while navigating patent claims on process and formulation.

Entry pathways that create risk

Alternative compliant manufacturing: A new supplier can enter if it avoids protected manufacturing steps and meets identical or acceptable quality specifications.
Clinically interchangeable tracer substitution: Even if not a generic in strict terms, payor behavior can shift demand if competing agents provide similar imaging utility.
Regionally sourced supply: Entry is fastest where radiopharmacy distribution is already fragmented and local licensing is straightforward.

Practical barriers to entry

Hot-lab operational readiness
QC release method validation
Supply chain continuity for radionuclide inputs
Patent litigation or licensing costs

How does Gallium Ga 68 edotreotide compare with competing somatostatin receptor PET tracers in market dynamics?

Answer: Market share depends on reimbursement, availability, and whether clinical pathways favor one tracer. Competitive pressure usually appears first where payors negotiate across radiopharmaceutical classes.

Competitive set (market behavior lens)

Other somatostatin receptor PET agents: Compete on imaging performance claims, clinical guideline inclusion, and payer coverage.
Availability differences: Supply reliability can drive utilization independent of marginal imaging performance.
Pricing and tendering: Hospitals often prefer the lowest total cost of ownership aligned with acceptable image quality and workflow fit.

Commercial implications

If a competitor is tender-preferred, volumes shift quickly regardless of historical use.
If payors require specific labeling or indications, substitution may lag even when clinical interchangeability is plausible.

What is the Orange Book status of Gallium Ga 68 edotreotide and how does it affect US market exclusivity?

Answer: The US patent and exclusivity landscape is determined by listed drug products and associated patents in the Orange Book, plus any statutory exclusivities that apply. Without reliable Orange Book listing data available in this dataset, a factual status call cannot be made here.

What patent litigation or Paragraph IV-type challenges affect Gallium Ga 68 edotreotide?

Answer: Radiopharmaceutical litigation risk usually centers on process/formulation claims and disputes over whether an alternative manufacture infringes. This dataset contains no litigation-specific docket or case identifiers sufficient for a factual timeline.

What FDA regulatory pathway governs Gallium Ga 68 edotreotide and how does that influence commercialization?

Answer: Commercial availability hinges on the regulatory approval status of the marketed radiopharmaceutical and its manufacturing authorization framework. This dataset does not provide enough FDA action identifiers to enumerate approval pathway elements.

Regulatory commercialization constraints that matter financially

Manufacturing site authorization and controls: Impacts supply capacity and distribution scale.
Radiopharmaceutical stability and handling requirements: Drives operational cost and logistics.
Label instructions and use claims: Limits off-label substitution in practice and affects hospital protocol adoption.

What does the competitive landscape look like by geography and channel (hospital vs nuclear medicine vs radiopharmacy networks)?

Answer: Distribution is dominated by radiopharmacy networks serving hospital imaging departments. Geography matters because PET infrastructure and reimbursement vary, and because radiopharmacy licensing can be a binding constraint.

Channel dynamics

Hospital imaging departments: Drive utilization and protocol selection.
Radiopharmacies: Control supply timing and QC workflow; can influence what tracers are available for scheduling.
National procurement frameworks and tenders: Set price and supply obligations for multiple hospitals simultaneously.

Geographic patterns

High PET density regions: Faster ramp, better economies of scale, stronger volume stability.
Low PET penetration regions: Growth depends on infrastructure investments and payer authorization.

Revenue exposure: which market segments and indications drive financial outcomes?

Answer: Revenue is driven by the volume of NET imaging studies and associated clinical pathways (staging, restaging, and treatment planning). The larger revenue pool typically sits in mature NET diagnostic centers where repeat imaging is routine.

Segment-level exposure levers

NET prevalence in insured populations
Frequency of follow-up imaging
Oncology center concentration
Pathology-to-imaging referral patterns
Payer rules for PET imaging authorization

What product, process, and formulation IP barriers most influence manufacturing and pricing power?

Answer: Process and formulation claims most strongly affect whether alternatives can enter without licensing or redesign.

IP barrier types

Labeling and preparation steps: Can be hard to replicate without infringing.
Kit composition: Even small compositional differences can reduce infringement risk, but may trigger new bridging studies for quality comparability.
QC method claims: Can constrain the ability to meet required release specs.

Pricing power linkage

If entry is blocked or delayed, the incumbent maintains higher net pricing.
If substitutes are legally viable, hospitals shift procurement toward the best total cost and reliable supply.

Key Takeaways

Gallium Ga 68 edotreotide demand is primarily driven by PET/CT adoption and NET diagnostic intensity, with availability and reimbursement setting the real ceiling.
Financial trajectory is typically regionally uneven, with ramp tied to radiopharmacy network build-out and payer coverage.
Margin pressure comes from radiopharmacy operating costs and supply-chain radionuclide economics, and from tender-based price competition.
Patent and regulatory exclusivity affect whether alternative suppliers can legally manufacture and commercialize; for radiopharmaceuticals, process and formulation IP often create the highest practical barrier.
Competitive pressure is shaped less by “molecule-level” differentiation and more by tender outcomes, supply reliability, and substitution behavior among payors and hospitals.

FAQs

1) What reimbursement policies most affect Gallium Ga 68 edotreotide net sales?

Reimbursement rules governing PET imaging coverage, tracer-specific reimbursement rates, and authorization criteria for NET workups are the dominant drivers of realized net price and volume.

2) How does radiopharmacy capacity change the ability to scale Gallium Ga 68 edotreotide volumes?

Hot-lab licensing, QC release throughput, and local supply lead times determine whether hospitals can schedule consistent imaging volume, which directly limits sales growth.

3) Which cost components most compress gross margin for Ga-68 PET tracers?

Radionuclide input costs, QC release labor, stability-linked logistics, and distribution overhead are typically the largest swing factors.

4) What substitutability risks exist from other somatostatin receptor PET agents?

Hospitals can switch utilization through formularies and tenders when alternative tracers are similarly reimbursed and reliably supplied, causing rapid volume redirection.

5) What indicators best predict whether competitive entry will reduce pricing?

Tender awards, competitor stocking in radiopharmacies, changes in net price per scan, and any evidence of alternate-supply availability in major PET hubs are leading indicators.

References

[No sourceable citations were available from the provided dataset for this specific drug’s Orange Book, patent numbers, litigation dockets, FDA milestones, or verified financial figures.]

US Patents:	0
Tradenames:	1
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
DailyMed Link:	gallium ga-68 edotreotide at DailyMed

Summary for gallium ga-68 edotreotide

Recent Clinical Trials for gallium ga-68 edotreotide